Pharmaceutical Technology Europe, Mar 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Mar 1, 2012
Special Feature
Single-Use Redundant Filtration
By Ranjeet Patil , Michael Felo , George Oulundsen
The authors describe a new assembly for bulk and final drug product filling operations.
Peer-Reviewed Research
Evaluating Impurities in Drugs (Part II of III)
In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.
Industry Insider
Stepping Up the Fight Against Counterfeits
By Nathan Jessop
Traditionally more prevalent in less industrialised regions, counterfeit medicines are now more frequently entering the heavily regulated supply chains of EU countries.
Outsourcing Review
CMOs Face a Kodak Moment
The evolving bio/pharmaceutical business model poses risk for CMOs.
Ask the Expert
Parametric release and real-time release testing
By Heribert Häusler
Boehringer Ingelheim's Heribert Häusler tells us about parametric release and real-time testing.
News
News: Market Boom for Generics
By Stephanie Sutton
The pharma industry has reached the long-dreaded patent cliff, but for copycat products, business is booming.
Ingredients
Securing the Pharma Supply Chain
Regulatory bodies, standard-setting organizations, and industry seek to tackle the problem of counterfeit drugs and securing the flow of pharma ingredients.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here